Skip to content

Private Equity Advancing Healthcare & Life Sciences Innovation

Ampersand is dedicated to Forging Leaders in Healthcare & Life Sciences. We focus on empowering our portfolio companies and partnering closely with founders and leadership teams to build value together.

By maintaining their positions at the helm, these leaders can fully realize their visions, strengthened by the collaboration with Ampersand’s experienced team. Our commitment to these partnerships helps ensure that each company benefits from our deep industry knowledge and resources, driving innovation and success.

Our founder-focused approach is a defining tenet, working with the visionaries we support to execute their missions with precision and confidence while benefiting from our team’s strategic support and life sciences knowledge.

 Hear from Our Portfolio Companies
  • The Firm recognitions presented are from third-parties that are not affiliated with Ampersand Capital Partners. These third-parties independently assess nominees based on multiple criteria. The awards and designations presented are the opinion of the respective parties conferring the award or designation and not of Ampersand. Recognitions by third-parties are not indicative of future performance. Ampersand may pay a licensing or related fee to participate and/or distribute the results. The receipt of compensation influences and is likely to present a potential material conflict of interest, relating to any granted award or designation. There can be no assurance that other providers or surveys would reach the same conclusions as the foregoing. Please also see the individual award icons and their respective hyperlinks to review the specific recognition disclaimers in full detail.

Founder & CEO Stories

Tjoapack
Case Study Read More

The Tjoapack Story
NuvinkaDx
Case Study Read More

The NuvinkaDx Story
Resolian
Case Study Read More

The Resolian Story
Vibalogics
Case Study Read More

Stefan Beyer:
The Vibalogics Story
Brammer Bio
Case Study Read More

Mark Bamforth:
The Brammer Bio Story
Adaptas
Case Study Read More

Jay Ray:
The Adaptas Solutions Story
Nexcelom
Case Study Read More

Peter Li & Jean Qiu:
The Nexcelom Story
Nexelis
Case Study Read More

Benoit Bouche:
The Nexelis Story
GENEWIZ
Case Study Read More

Amy Liao:
The GENEWIZ Story
Alcami
Case Study Read More

Pat Walsh:
The Alcami Story
Confluent
Case Study Read More

Dean Schauer:
The Confluent Story

Our founder-focused approach is not only an investment strategy, but a deep commitment to fostering an environment where founders remain at the helm of their organizations while benefiting from the guidance and collaboration offered by the experienced Ampersand team.

Explore Founder & CEO Stories

Enabling Growth on a Global Scale

With more than 30 years dedicated to the life sciences sector and a global presence supported by offices in North America and Europe, Ampersand Capital Partners has built a strong reputation and notable history as an industry leader at the forefront of transformative investments serving science. However, we are more than investors; we are passionate about science and collaborative business partners forging the next generation of healthcare leaders.

HQ Facility
View Our Portfolio
Please enable javascript to see our interactive globe.
Drag to rotate

Deep Experience Across Core Life Sciences Segments

Read More

Laboratory Products
Read More

Laboratory Services
Read More

Contract Manufacturing
Read More

Pharma Services
Read More

Specialty Products

Our Focus & Expertise

Investment Criteria

Company Size

Typically $ to $ million in revenue
at least $ to $ million of EBITDA

Investment Size

$ to $ million of equity

Ownership

Either majority or minority positions

Geography

North America
Europe
APAC
Learn More

The investment criteria presented herein serves as a general guideline and is provided for illustrative purposes only.  Ampersand may deviate from these guidelines in its discretion.  Accordingly, the actual investments may differ materially from the guideline set out herein.  There is no assurance that investment made pursuant to these guidelines will result in a positive investment performance.

Industry Insights

Market Sector
A Fast, Simplified Approach to Quantitative Headspace Analysis of Volatile Impurities in Drug and Packaging Products
  • Lab Products
  • Articles
Read More

A Fast, Simplified Approach to Quantitative Headspace Analysis of Volatile Impurities in Drug and Packaging Products
Cryo-EM for Epitope Mapping
  • Lab Services
  • Webinars

Cryo-EM for Epitope Mapping
Advantages of Cas9 mRNA for Gene Editing: Precision, Control & Cost Effective
  • Pharma Services
  • Blogs

Advantages of Cas9 mRNA for Gene Editing:
Precision, Control & Cost Effective
The evolving mRNA landscape
  • Pharma Services
  • Articles

The evolving mRNA landscape
Treatment of Long Bone Nonunion: The Role of the Diamond Concept
  • Specialty Products
  • Videos

Treatment of Long Bone Nonunion:
The Role of the Diamond Concept
View All

Latest News

Explore All News
News Read More
August 27, 2026

Ampersand Capital Partners Recognized Among GrowthCap’s Top Private Equity Firms of 2026

  • Ampersand News
News Read More
July 9, 2026

Ampersand Ranks #6 Globally in HEC Paris–Dow Jones Growth Capital Performance Ranking

  • Ampersand News
News Read More
July 6, 2026

Ampersand’s Melanie Fan, Partner, Named a Top Women Leader in Growth Investing of 2026 by GrowthCap

  • Ampersand News
News Read More
June 30, 2026

Corten Capital and Ampersand Capital Partners Complete Acquisition of Beacon Intelligence to Accelerate Growth in Life Sciences R&D Intelligence

  • Ampersand News
News Read More
June 9, 2026

VIVEbiotech Adds Newest in vivo Lentiviral Vector-based Therapeutic Programs

  • Portfolio Company News
News Read More
June 4, 2026

Purna Pharmaceuticals Names Marc Verbruggen as Managing Director

  • Portfolio Company News
News Read More
May 28, 2026

Ampersand Closes Oversubscribed Fund at $1.5 Billion Hard Cap

  • Ampersand News
News Read More
May 5, 2026

Ampersand Capital Partners Completes Sale of Tjoapack to Alcami

  • Ampersand News
  • Portfolio Company News
News Read More
March 17, 2026

MedPharm Welcomes Palvella Therapeutics’ Positive Topline Results from Its Phase 3 Study of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

  • Portfolio Company News
News Read More
March 10, 2026

NanoImaging Services Appoints Fraser McLeod as Chief Executive Officer to Lead Next Phase of Growth

  • Portfolio Company News

Ampersand Capital Partners LLC (“Ampersand”) is a registered investment adviser. Ampersand’s website is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of Ampersand’s web site on the Internet should not be construed by any consumer and/or prospective client as Ampersand’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet. Any subsequent, direct communication by Ampersand with a prospective client shall be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides. A copy of Ampersand’s current written disclosure statement discussing Ampersand’s business operations, services, and fees is available at the SEC’s investment adviser public information website – www.adviserinfo.sec.gov or from Ampersand upon written request. Ampersand does not make any representations or warranties as to the accuracy, timeliness, suitability, completeness, or relevance of any information prepared by any unaffiliated third party, whether linked to Ampersand’s web site or incorporated herein, and takes no responsibility therefor. All such information is provided solely for convenience purposes only and all users thereof should be guided accordingly. This website and information are provided for guidance and information purposes only. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy. This website and information are not intended to provide investment, tax, or legal advice.